RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced today that it anticipates the filing of its annual financial statements, management’s discussion and analysis, annual information form and related officer certifications for the financial year ended July 31, 2021 (collectively, the “Annual Filings”) will be delayed beyond the required filing deadline under Parts 4 and 5 of National Instrument 51-102 – Continuous Disclosure Obligations (“NI 51-102”) and pursuant to National Instrument 52-109 – Certification of Disclosure in Issuer’s Annual and Interim Filings, being October 29, 2021 (the “Filing Deadline”).
- 0 Comments
- FY2021